Healthy VolunteersPhase 1NCT03435276
Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects
A Phase 1 study testing AZD9977 in people with Healthy Volunteers, run by AstraZeneca at 1 site in United Kingdom.
Trial summary
This is a randomized, single-blind, placebo-controlled study conducted on healthy male subjects at a single study center to assess the safety, tolerability and the pharmacokinetics of AZD9977 following multiple-ascending oral doses at steady state Read more about this study
- Who is it for?
- Ages 18 to 50 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers
- What is being tested?
- AZD9977
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 27 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 27 Feb 2018to 13 Jun 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Provision of signed and dated, written informed consent before any study specific procedures.
- Healthy male subject aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
- Have a body mass index (BMI) between 18 and 30 kg/m2(inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive).
- Provision of signed, written and dated informed consent for optional genetic and/or biomarker research. If a subject declines to participate in the genetic components of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study.
Who cannot join
- History of any clinically important disease/disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study/influence the results/subject's ability to participate in the study.
- History/presence of gastrointestinal, hepatic/renal disease/any other condition known to interfere with absorption, distribution, metabolism/excretion of drugs.
- Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the 1st administration of the IMP.
- Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results at the Screening Visit and/or admission, as judged by the Investigator and specified below: Serum potassium > 5.0 mmol/L; Hemoglobin A1c (HbA1c) > 5.7%.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody \& human immunodeficiency virus (HIV).
- Abnormal vital signs, after 10 minutes supine rest at the Screening Visit and/or admission, defined as any of the following: Systolic BP < 90 mmHg or > 140 mmHg; Diastolic BP < 50 mmHg or > 90 mmHg; Heart rate < 45 or > 85 beats per minute (bpm).
Show all 28Show fewer
- Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG as judged by the Investigator that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology, particularly in the CSP defined primary lead or LV hypertrophy at the Screening Visit or/and admission.
- Prolonged QT interval corrected for HR by Fridericia's formula (QTcF) > 450 ms or shortened QTcF < 340 ms or family history of long QT syndrome.
- PR (PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular preexcitation).
- PR (PQ) interval prolongation (> 240 ms intermittent second (Wenckebach block while asleep is not exclusive) or 3rd degree atrioventricular (AV) block, or AV dissociation.
- Persistent/intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of ventricular hypertrophy or pre-excitation.
- Known or suspected history of drug abuse in the last 12 months before the Screening Visit as judged by the Investigator.
- Current smokers/those who have smoked/used nicotine products (including e-cigarettes) within last 3 months before the Screening Visit.
- History of alcohol abuse in the last 12 months before the Screening Visit/current excessive intake of alcohol as judged by the Investigator.
- Positive screen for drugs of abuse, alcohol/cotinine (nicotine) at the Screening Visit/admission.
- History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.
- Excessive intake of caffeine-containing drinks/food (e.g., coffee, tea, chocolate,) as judged by the Investigator.
- Use of drugs with enzyme inducing properties like St John's Wort within 3 weeks before the 1st administration of the IMP.
- Use of any prescribed/non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks before the first administration of the IMP or longer if the medication has a long half-life.
- Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months before the Screening Visit.
- Has received another new chemical/non-chemical entity (a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The exclusion period 3 months after the final dose/1 month after the last visit whichever is the longest.
- Subjects who have previously received AZD9977.
- Involvement of any Astra Zeneca or study site employee or their close relatives.
- Judgment by the Investigator that the subject should not participate in the study if they have any ongoing/recent (during the Screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
- Subjects who cannot communicate reliably with the Investigator.
- Vulnerable subjects (kept in detention, protected adults under guardianship, trusteeship or committed to an institution by governmental or juridical order).
- Previous bone marrow transplant.
- Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Multiple-Ascending Dose Administration in Healthy Volunteers
This is a randomized, single-blind, placebo-controlled study conducted on healthy male subjects at a single study center to assess the safety, tolerability and the pharmacokinetics of AZD9977 following multiple-ascending oral doses at steady state
Read the detailed description
This is a phase 1, randomized, single-blind, placebo-controlled, single center, multiple-ascending dose sequential-group design study conducted on 45 healthy male subjects to investigate the safety, tolerability, pharmacokinetics (PK) of AZD9977, time to reach steady state, the degree of accumulation and the time dependency of the PK. The study consists of three visits:
- A screening period (maximum 28 days)
- A treatment period (subjects will be resident from 2 days before first dose of investigation medicinal product (IMP) (Day -2) until at least 36 after last dose of IMP and will be discharged on Day 9) and
- A follow-up visit within 5 to 7 days after last dose of IMP. This study consists of 3 Cohorts (9 subjects each). Based on the safety review committee (SRC) requirement, 2 additional cohorts may be added either to repeat a dose level or additional dose steps, if required. In each cohort, subjects will be randomized to receive AZD9977 (6 subjects) and placebo (3 subjects) oral suspension twice daily. The dose of AZD9977 in Cohort 1 will be 50 mg as starting dose and in Cohort 2 and 3 at provisional dose 150 mg and 300 mg, respectively. Each subject will receive a total of 14 oral doses of AZD9977 or placebo. Each subject will receive a single dose of IMP in the morning of Day 1 and Day 8 and twice daily doses on Day 2 to Day 7.
On Day 1 and Day 8, subjects will be fasted for 10 hours before dosing until 4 hours after dosing when lunch will be served. On Day 2 to Day 6, subjects will be fasted for 10 hours before dosing until 1 hour after dosing when breakfast will be served. On Day 7, subjects will be fasted for 10 hours before dosing and until after the completion of the oral glucose tolerance test (OGTT) when breakfast will be served. For the evening dose of IMP (Days 2 to Day 7), subjects will be fasted for 2 hours before dosing until 1 hour after dosing. On all days, subjects will be allowed to drink freely until 1 hour before dosing to prevent dehydration before each morning and evening dose and water consumption could be resumed 1 hour after dosing.
Dosing for each ascending dose cohort will proceed with 2 subjects in a sentinel cohort, such that 1 subject will be randomized to receive placebo and 1 subject will be randomized to receive AZD9977. The safety data from the sentinel subjects up to 72 hours post first dose will be reviewed by the principal investigator (PI) before the remaining subjects in the cohort are dosed. Following review of data from the study, the SRC may decide to adjust the length of the stay at the study site and the timing and number of assessments and/or blood samples for subsequent cohorts. The time window between the single dose and start of repeated dosing may also be adjusted. The duration of the study is approximately 6 weeks
- Conditions
- Healthy Volunteers
- Being tested
- AZD9977, Placebo
- Keywords
- Heart failure., Oral selective mineralocorticoid receptor modulator., Heart failure with preserved ejection fraction (HFpEF).
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AZD9977Drug
Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
PlaceboOther
Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | Experimental | Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7 Receives: Drug: AZD9977; Other: Placebo |
| Cohort 2 | Experimental | Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7 Receives: Drug: AZD9977; Other: Placebo |
| Cohort 3 | Experimental | Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7 Receives: Drug: AZD9977; Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of subjects with adverse events (AEs) due to AZD9977
To assess AEs as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. AEs will be collected from the start of screening throughout the treatment period up to and including the follow-up visit. Serious AEs will be recorded from the time of informed consent.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Systolic blood pressure [SBP]
To measure SBP as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. SBP will be collected after the subject has rested in the supine position for at least 10 minutes.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Diastolic blood pressure [DBP]
To measure DBP as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. DBP will be collected after the subject has rested in the supine position for at least 10 minutes.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Pulse rate
To measure pulse as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Pulse rate will be collected after the subject has rested in the supine position for at least 10 minutes.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments of urine volume
To assess the urine volume as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Number of participants with abnormal findings in Twelve-lead (12-Lead) electrocardiograms (ECGs) (safety ECGs and 12-lead continuous digital ECG [dECG])
To assess any clinically significant abnormalities on cardiac electrophysiological parameters as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. 12-lead safety ECG and dECG will be obtained after the participant rested in the supine position for at least 10 minutes. Safety ECG will be collected at the end of each dECG recording. Various dECG variables like time between 2 consecutive R waves on ECG (RR), ECG interval measured form onset of P wave to the onset of QRS complex (PR), ECG interval measured from onset of QRS complex to the J point (QRS) and ECG interval measured form onset of QRS complex to the end of the T wave (QT intervals) will be reported. Derived parameters like QT interval corrected for heart rate using Fridericia's formula (QTcF), heart rate (HR) and others, as applicable are also calculated.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Number of participants with abnormal cardiac telemetry
To assess any clinically significant abnormalities in the cardiovascular system functioning as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. A 2-lead real-time telemetry ECG will be used to assess the heart rate.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Number of participants with abnormal physical examination findings
To assess any clinically significant abnormal physical examination findings as a variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Brief physical examination includes assessment of the general appearance, skin, cardiovascular system, respiratory and abdomen. Full physical examination includes assessment of the general appearance, skin, cardiovascular, respiratory, abdomen, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculoskeletal and neurological systems.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Differential count
To assess the differential white blood cell count (absolute count of basophils, eosinophils, lymphocytes, monocyets and neutrophils) as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Hematocrit (HCT) and Reticulocyte absolute count
To assess the HCT (red blood cells [RBC]) and reticulocyte absolute count (immature RBCs) as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Hemoglobin (Hb)
To assess the Hb as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)
To assess the MCH as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)
To assess the MCHC as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Mean corpuscular volume (MCV)
To assess the MCV as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Platelets
To assess platelets count as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Hematology - Blood cells count
To assess RBC and white blood cells (WBC) count as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Albumin
To assess the serum albumin level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - C reactive protein (CRP)
To assess the serum CRP level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Creatine kinase (CK)
To assess the serum CK level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Creatinine
To assess the serum creatinine level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Glucose (fasting)
To assess the serum fasting glucose level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Calcium, potassium, phosphate and sodium
To assess the serum calcium, potassium, phosphate and sodium level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Urea and Uric acid
To assess the serum urea and uric acid level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Liver enzymes
To assess the serum Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST) and Gamma glutamyl transpeptidase (GGT) level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Bilirubin
To assess the serum bilirubin (total and unconjugated) level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Steroid
To assess the serum cholesterol and triglycerides level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Luteinizing hormone (LH)
To assess the serum LF level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Sex hormone binding globulin (SHBG)
To assess the serum SHBG level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Testosterone
To assess the serum testosterone level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Aldosterone
To assess the serum aldosterone level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Hemoglobin A1c (HbA1c)
To assess the serum HbA1c level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - High-sensitivity troponin T
To assess the serum high-sensitivity troponin T level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - N-terminal pro-brain natriuretic peptide (NT-proBNP)
To assess the serum NT-proBNP level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Serum Clinical chemistry - Follicle-stimulating hormone (FSH)
To assess the serum FSH level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Clinical Urinalysis - Protein
To assess the urine protein level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. If urinalysis is positive for protein, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Clinical Urinalysis - Blood
To assess the urine blood level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. If urinalysis is positive for blood, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Clinical Urinalysis - Glucose
To assess the urine glucose level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Clinical Urinalysis - Uric acid
To assess the urine uric acid level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Clinical Urinalysis - Creatinine
To assess the urine creatinine level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Laboratory assessments: Urinalysis - Urinary Electrolytes
To assess the urine electrolytes level (calcium, chloride, potassium and sodium) as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Measured: From baseline up to follow-up (5 to 7 days post last dose)
Secondary outcomes (21)
Plasma PK parameter: Observed maximum plasma concentration (Cmax)
To assess Cmax after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Time to reach maximum concentration (tmax)
To assess tmax after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Terminal half-life (t1/2λz)
To assess t1/2λz after administration of multiple dose of AZD9977 oral suspension; estimated as (ln2)/λz
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Terminal rate constant (λz)
To assess λz after administration of multiple dose of AZD9977 oral suspension; estimated by log-linear least squares regression of the terminal part of the concentration-time curve
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Area under the plasma concentration-time curve in the dosing interval (AUCτ)
To assess AUCτ after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUClast)
To assess AUClast after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period:Day 1and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Apparent volume of distribution for parent drug at terminal phase (Vz/F)
To assess Vz/F after administration of multiple dose of AZD9977 oral suspension, estimated by dividing the apparent
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Apparent clearance for parent drug (CL/F)
To assess CL/F after administration of multiple dose of AZD9977 oral suspension, estimated as dose divided by AUC
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized AUCτ (AUCτ/D)
To assess AUCτ/D after administration of multiple dose of AZD9977 oral suspension, estimated by dividing AUCτ by the dose administered
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized Cmax (Cmax/D)
To assess Cmax/D after administration of multiple dose of AZD9977 oral suspension, estimated by dividing Cmax by the dose administered
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Mean Residence Time (MRT)
To assess MRT after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Area under the concentration-time curve from time zero extrapolated to infinity (AUC)
To assess AUC after administration of multiple dose of AZD9977 oral suspension. AUC is estimated by AUClast+ Clast/λz where Clast is the last observed quantifiable concentration
Measured: Treatment period:Day 1 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized AUC (AUC/D)
To assess AUC/D after administration of multiple dose of AZD9977 oral suspension. AUC is estimated by dividing AUC by the dose administered.
Measured: Treatment period:Day 1 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized AUClast (AUClast/D)
To assess AUClast/D after administration of multiple dose of AZD9977 oral suspension; estimated by dividing AUClast by the dose administered.
Measured: Treatment period:Day 1 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Observed concentration at the end of the dosing interval (Cmin)
To assess Cmin after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Accumulation ratio for AUCτ (Rac AUCτ)
To assess Rac AUCτ after administration of multiple dose of AZD9977 oral suspension; estimated by dividing AUCτ from the last dosing day by AUCτ on Day 1
Measured: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Accumulation ratio for AUCτ (Rac Cmax)
To assess Rac Cmax after administration of multiple dose of AZD9977 oral suspension; estimated by dividing maximum (peak) steady-state plasma drug concentration (Css,max) from the last dosing day by Cmax on Day 1
Measured: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Temporal change (TCP)
To assess TCP after administration of multiple dose of AZD9977 oral suspension; estimated by dividing AUCτ from the last dosing day by AUC on Day 1
Measured: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Urine PK parameter: Renal clearance (CLR)
To assess CLR after administration of multiple dose of AZD9977 oral suspension; estimated by dividing amount of analyte excreted into urine (Ae[0-t]) by AUC(0-t) where the time interval for both parameters are the same
Measured: Treatment period: Day 8 (Pre-dose and 0-4, 4-8 and 8-12 hours post-dose)
Urine PK parameter: Amount of analyte excreted into the urine from time t1 to t2 (Ae[t1-t2])
To assess Ae(t1-t2) after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period: Day 8 (Pre-dose and 0-4, 4-8 and 8-12 hours post-dose)
Urine PK parameter: Percentage Fraction of dose excreted in urine from time t1 to t2 (fe[t1-t2]%)
To assess fe(t1-t2)% after administration of multiple dose of AZD9977 oral suspension.
Measured: Treatment period: Day 8 (Pre-dose and 0-4, 4-8 and 8-12 hours post-dose)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2018
- Study start27 Feb 2018
- Primary completion13 Jun 2018
- Study completion13 Jun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Parexel
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03435276
- Sponsor's protocol ID
- D6401C00001
- Status last verified
- Jun 2018
- First submitted
- 25 Jan 2018
- Last updated
- 21 Jun 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jun 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Multiple-Ascending Dose Administration in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT03435276
- Acronym / sponsor ID
- D6401C00001
- Conditions
- Healthy Volunteers
- Keywords
- Heart failure., Oral selective mineralocorticoid receptor modulator., Heart failure with preserved ejection fraction (HFpEF).
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Collaborators
- Parexel
- Study start
- 27 Feb 2018 (actual)
- Primary completion
- 13 Jun 2018 (actual)
- Study completion
- 13 Jun 2018 (actual)
- First posted
- 19 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, single-blind, placebo-controlled study conducted on healthy male subjects at a single study center to assess the safety, tolerability and the pharmacokinetics of AZD9977 following multiple-ascending oral doses at steady state
Detailed description
This is a phase 1, randomized, single-blind, placebo-controlled, single center, multiple-ascending dose sequential-group design study conducted on 45 healthy male subjects to investigate the safety, tolerability, pharmacokinetics (PK) of AZD9977, time to reach steady state, the degree of accumulation and the time dependency of the PK. The study consists of three visits:
- A screening period (maximum 28 days)
- A treatment period (subjects will be resident from 2 days before first dose of investigation medicinal product (IMP) (Day -2) until at least 36 after last dose of IMP and will be discharged on Day 9) and
- A follow-up visit within 5 to 7 days after last dose of IMP. This study consists of 3 Cohorts (9 subjects each). Based on the safety review committee (SRC) requirement, 2 additional cohorts may be added either to repeat a dose level or additional dose steps, if required. In each cohort, subjects will be randomized to receive AZD9977 (6 subjects) and placebo (3 subjects) oral suspension twice daily. The dose of AZD9977 in Cohort 1 will be 50 mg as starting dose and in Cohort 2 and 3 at provisional dose 150 mg and 300 mg, respectively. Each subject will receive a total of 14 oral doses of AZD9977 or placebo. Each subject will receive a single dose of IMP in the morning of Day 1 and Day 8 and twice daily doses on Day 2 to Day 7.
On Day 1 and Day 8, subjects will be fasted for 10 hours before dosing until 4 hours after dosing when lunch will be served. On Day 2 to Day 6, subjects will be fasted for 10 hours before dosing until 1 hour after dosing when breakfast will be served. On Day 7, subjects will be fasted for 10 hours before dosing and until after the completion of the oral glucose tolerance test (OGTT) when breakfast will be served. For the evening dose of IMP (Days 2 to Day 7), subjects will be fasted for 2 hours before dosing until 1 hour after dosing. On all days, subjects will be allowed to drink freely until 1 hour before dosing to prevent dehydration before each morning and evening dose and water consumption could be resumed 1 hour after dosing.
Dosing for each ascending dose cohort will proceed with 2 subjects in a sentinel cohort, such that 1 subject will be randomized to receive placebo and 1 subject will be randomized to receive AZD9977. The safety data from the sentinel subjects up to 72 hours post first dose will be reviewed by the principal investigator (PI) before the remaining subjects in the cohort are dosed. Following review of data from the study, the SRC may decide to adjust the length of the stay at the study site and the timing and number of assessments and/or blood samples for subsequent cohorts. The time window between the single dose and start of repeated dosing may also be adjusted. The duration of the study is approximately 6 weeks
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 | Experimental | Drug: AZD9977, Other: PlaceboRandomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7 |
| Cohort 2 | Experimental | Drug: AZD9977, Other: PlaceboRandomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7 |
| Cohort 3 | Experimental | Drug: AZD9977, Other: PlaceboRandomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7 |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Provision of signed and dated, written informed consent before any study specific procedures.
- Healthy male subject aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
- Have a body mass index (BMI) between 18 and 30 kg/m2(inclusive) and weigh at least 50 kg and no more than 100 kg (inclusive).
- Provision of signed, written and dated informed consent for optional genetic and/or biomarker research. If a subject declines to participate in the genetic components of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study.
Key exclusion criteria (28 listed)
- History of any clinically important disease/disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study/influence the results/subject's ability to participate in the study.
- History/presence of gastrointestinal, hepatic/renal disease/any other condition known to interfere with absorption, distribution, metabolism/excretion of drugs.
- Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the 1st administration of the IMP.
- Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results at the Screening Visit and/or admission, as judged by the Investigator and specified below: Serum potassium > 5.0 mmol/L; Hemoglobin A1c (HbA1c) > 5.7%.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody \& human immunodeficiency virus (HIV).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AZD9977Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3 | Drug | Cohort 1, Cohort 2, Cohort 3 |
| PlaceboRandomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3 | Other | Cohort 1, Cohort 2, Cohort 3 |
Primary outcome
Number of subjects with adverse events (AEs) due to AZD9977
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess AEs as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. AEs will be collected from the start of screening throughout the treatment period up to and including the follow-up visit. Serious AEs will be recorded from the time of informed consent.
Systolic blood pressure [SBP]
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To measure SBP as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. SBP will be collected after the subject has rested in the supine position for at least 10 minutes.
Diastolic blood pressure [DBP]
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To measure DBP as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. DBP will be collected after the subject has rested in the supine position for at least 10 minutes.
Pulse rate
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To measure pulse as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Pulse rate will be collected after the subject has rested in the supine position for at least 10 minutes.
Laboratory assessments of urine volume
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the urine volume as variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Number of participants with abnormal findings in Twelve-lead (12-Lead) electrocardiograms (ECGs) (safety ECGs and 12-lead continuous digital ECG [dECG])
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess any clinically significant abnormalities on cardiac electrophysiological parameters as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. 12-lead safety ECG and dECG will be obtained after the participant rested in the supine position for at least 10 minutes. Safety ECG will be collected at the end of each dECG recording. Various dECG variables like time between 2 consecutive R waves on ECG (RR), ECG interval measured form onset of P wave to the onset of QRS complex (PR), ECG interval measured from onset of QRS complex to the J point (QRS) and ECG interval measured form onset of QRS complex to the end of the T wave (QT intervals) will be reported. Derived parameters like QT interval corrected for heart rate using Fridericia's formula (QTcF), heart rate (HR) and others, as applicable are also calculated.
Number of participants with abnormal cardiac telemetry
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess any clinically significant abnormalities in the cardiovascular system functioning as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. A 2-lead real-time telemetry ECG will be used to assess the heart rate.
Number of participants with abnormal physical examination findings
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess any clinically significant abnormal physical examination findings as a variable of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. Brief physical examination includes assessment of the general appearance, skin, cardiovascular system, respiratory and abdomen. Full physical examination includes assessment of the general appearance, skin, cardiovascular, respiratory, abdomen, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculoskeletal and neurological systems.
Laboratory assessments: Hematology - Differential count
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the differential white blood cell count (absolute count of basophils, eosinophils, lymphocytes, monocyets and neutrophils) as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Hematology - Hematocrit (HCT) and Reticulocyte absolute count
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the HCT (red blood cells [RBC]) and reticulocyte absolute count (immature RBCs) as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Hematology - Hemoglobin (Hb)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the Hb as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the MCH as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the MCHC as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Hematology - Mean corpuscular volume (MCV)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the MCV as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Hematology - Platelets
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess platelets count as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Hematology - Blood cells count
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess RBC and white blood cells (WBC) count as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Albumin
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum albumin level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - C reactive protein (CRP)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum CRP level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Creatine kinase (CK)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum CK level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Creatinine
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum creatinine level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Glucose (fasting)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum fasting glucose level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Calcium, potassium, phosphate and sodium
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum calcium, potassium, phosphate and sodium level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Urea and Uric acid
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum urea and uric acid level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Liver enzymes
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST) and Gamma glutamyl transpeptidase (GGT) level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Bilirubin
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum bilirubin (total and unconjugated) level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Steroid
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum cholesterol and triglycerides level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Luteinizing hormone (LH)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum LF level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Sex hormone binding globulin (SHBG)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum SHBG level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Testosterone
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum testosterone level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Aldosterone
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum aldosterone level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Hemoglobin A1c (HbA1c)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum HbA1c level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - High-sensitivity troponin T
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum high-sensitivity troponin T level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - N-terminal pro-brain natriuretic peptide (NT-proBNP)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum NT-proBNP level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Serum Clinical chemistry - Follicle-stimulating hormone (FSH)
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the serum FSH level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Clinical Urinalysis - Protein
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the urine protein level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. If urinalysis is positive for protein, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).
Laboratory assessments: Clinical Urinalysis - Blood
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the urine blood level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension. If urinalysis is positive for blood, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).
Laboratory assessments: Clinical Urinalysis - Glucose
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the urine glucose level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Clinical Urinalysis - Uric acid
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the urine uric acid level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Clinical Urinalysis - Creatinine
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the urine creatinine level as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
Laboratory assessments: Urinalysis - Urinary Electrolytes
Time frame: From baseline up to follow-up (5 to 7 days post last dose)
To assess the urine electrolytes level (calcium, chloride, potassium and sodium) as variables of safety and tolerability after administration of multiple dose of AZD9977 oral suspension.
21 secondary outcomes
Plasma PK parameter: Observed maximum plasma concentration (Cmax)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Time to reach maximum concentration (tmax)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Terminal half-life (t1/2λz)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Terminal rate constant (λz)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Area under the plasma concentration-time curve in the dosing interval (AUCτ)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUClast)
Time frame: Treatment period:Day 1and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Apparent volume of distribution for parent drug at terminal phase (Vz/F)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Apparent clearance for parent drug (CL/F)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized AUCτ (AUCτ/D)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized Cmax (Cmax/D)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Mean Residence Time (MRT)
Time frame: Treatment period:Day 1 and Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Area under the concentration-time curve from time zero extrapolated to infinity (AUC)
Time frame: Treatment period:Day 1 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized AUC (AUC/D)
Time frame: Treatment period:Day 1 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Dose normalized AUClast (AUClast/D)
Time frame: Treatment period:Day 1 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Observed concentration at the end of the dosing interval (Cmin)
Time frame: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Accumulation ratio for AUCτ (Rac AUCτ)
Time frame: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Accumulation ratio for AUCτ (Rac Cmax)
Time frame: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Plasma PK parameter: Temporal change (TCP)
Time frame: Treatment period: Day 8 (Pre-dose & 20 min, 40 min, 1, 2, 4, 6, 8, 10, 12, 16, & 20 hours post-dose)
Urine PK parameter: Renal clearance (CLR)
Time frame: Treatment period: Day 8 (Pre-dose and 0-4, 4-8 and 8-12 hours post-dose)
Urine PK parameter: Amount of analyte excreted into the urine from time t1 to t2 (Ae[t1-t2])
Time frame: Treatment period: Day 8 (Pre-dose and 0-4, 4-8 and 8-12 hours post-dose)
Urine PK parameter: Percentage Fraction of dose excreted in urine from time t1 to t2 (fe[t1-t2]%)
Time frame: Treatment period: Day 8 (Pre-dose and 0-4, 4-8 and 8-12 hours post-dose)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jun 2018.
- Individual participant dataSharing planned: No
Related trials for Healthy Volunteers
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
Enrolling by invitationObservational study
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
Healthy Volunteer Samples
Not yet recruitingPhase 1
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Healthy Participants
RecruitingObservational study
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Eczema, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AZD9977 in people with Healthy Volunteers, run by AstraZeneca at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of subjects with adverse events (AEs) due to AZD9977 (time frame: From baseline up to follow-up (5 to 7 days post last dose)). The study lists 40 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2018.